| Literature DB >> 24597767 |
Yuanyuan Zhang, Yong Yang, Lei Chen1, Jianhong Zhang.
Abstract
BACKGROUND: Uveal melanoma is an aggressive cancer which has a high percentage metastasizing to the liver, with a worse prognosis. Identification of patients at high risk of metastases may provide information for early detection of metastases and treatment.Entities:
Mesh:
Year: 2014 PMID: 24597767 PMCID: PMC4015751 DOI: 10.1186/1471-2350-15-29
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Clinicopathologic characteristics of uveal melanoma patients
| Mean age, years | 60.96 ± 14.4 | 63.17 ± 10.21 |
| Mean primary tumor thickness (mm) | 10.13 ± 2.97 | 11.45 ± 2.76 |
| Mean tumor largest diameter (mm) | 14.64 ± 4.14 | 15.08 ± 4.01 |
| Gender, No. of patients | | |
| Male | 27 | 29 |
| Female | 18 | 17 |
| Location of tumor | | |
| Anterior | 3 | 4 |
| On equator | 29 | 27 |
| Posterior | 6 | 13 |
| All | 0 | 1 |
| NA | 7 | 1 |
| Histopathologic cell type | | |
| Epithelioid | 9 | 18 |
| Spindle | 8 | 18 |
| Mixed | 16 | 9 |
| NA | 12 | 1 |
| Extrascleral extension | | |
| No | 31 | 31 |
| Yes | 10 | 9 |
| NA | 4 | 6 |
| Chr 3 | | |
| Monosomy | 17 | 31 |
| Disomy | 24 | 6 |
| Partial monosomy | 2 | 3 |
| NA | 2 | 6 |
Clinicopathologic characteristics of uveal melanoma patients got from the published article and each GSM information. NA, not available.
Figure 1Unsupervised classification of uveal melanoma samples based on gene expression profiling. Classification of 91 uveal melanoma samples using the 1138-probe sets identified as differentially expressed between the 46 liver metastatic samples and the 45 non-metastatic samples. Expression data are depicted as a data matrix where each row represents a gene and each column represents a sample. Expression levels are depicted according to the color scale shown at the top. Red and green indicate expression levels, respectively, above and below the median. The magnitude of deviation from the median is represented by the color saturation.
Most obviously dysregulated genes sorted by P value in liver metastatic uveal melanoma compare to non-metastatic tumors
| NEURL1B | 1.67 × 10-9 | 51.47 | 88.42 | 1.72 |
| EXT1 | 2.82 × 10-9 | 203.15 | 362.35 | 1.78 |
| DERL1 | 4.89 × 10-9 | 178.31 | 412.54 | 2.31 |
| GALNTL4 | 1.22 × 10-8 | 57.44 | 128.49 | 2.24 |
| MR1 | 1.41 × 10-8 | 60.08 | 98.74 | 1.64 |
| DDX39 | 3.31 × 10-8 | 347.31 | 556.46 | 1.60 |
| HTR2B | 3.49 × 10-8 | 41.04 | 574.49 | 14.00 |
| RAB2A | 5.29 × 10-8 | 363.13 | 741.99 | 2.04 |
| C10orf26 | 6.68 × 10-8 | 376.40 | 569.30 | 1.51 |
| GJC1 | 7.39 × 10-8 | 25.95 | 75.05 | 2.89 |
| CHL1 | 8.99 × 10-8 | 80.84 | 17.12 | 0.21 |
| ZNF33B | 2.17 × 10-8 | 41.91 | 21.24 | 0.51 |
| OVOS2 | 2.44 × 10-8 | 857.96 | 185.87 | 0.22 |
| EIF1B | 3.35 × 10-7 | 1008.84 | 567.87 | 0.56 |
| PHLDA1 | 5.22 × 10-7 | 370.24 | 134.93 | 0.36 |
| PLSCR4 | 5.34 × 10-7 | 114.83 | 53.41 | 0.47 |
| MEGF10 | 8.38 × 10-7 | 165.39 | 26.05 | 0.16 |
| ZNF415 | 1.19 × 10-6 | 37.03 | 13.91 | 0.38 |
| ZNF667 | 1.25 × 10-6 | 34.08 | 16.02 | 0.47 |
| MEGF10 | 1.66 × 10-6 | 22.24 | 10.21 | 0.46 |
Most obviously dysregulated genes sorted by p value in liver metastatic uveal melanoma (n = 45) vs. non-metastatic tumors (n = 46).
Most obviously dysregulated genes with fold change absolute value > 3 in liver Metastatic Uveal Melanoma compare to non-metastatic tumors
| HTR2B | 3.49 × 10-8 | 5.36 | 9.17 | 14.00 |
| PPM1K | 2.96 × 10-6 | 7.67 | 9.39 | 3.30 |
| SSX4 | 1.03 × 10-4 | 5.65 | 7.28 | 3.09 |
| PTGER4 | 3.01 × 10-3 | 6.75 | 8.36 | 3.06 |
| MEGF10 | 8.38 × 10-7 | 7.37 | 4.70 | 0.16 |
| SYNPR | 1.25 × 10-5 | 9.15 | 6.83 | 0.20 |
| CHL1 | 8.99 × 10-8 | 6.34 | 4.10 | 0.21 |
| OVOS2 | 2.44 × 10-7 | 9.74 | 7.54 | 0.22 |
| LOC100128252 | 5.70 × 10-6 | 7.54 | 5.55 | 0.25 |
| MPPED2 | 5.58 × 10-6 | 6.28 | 4.40 | 0.27 |
| CNTN3 | 1.37 × 10-5 | 5.40 | 3.60 | 0.29 |
| PCDH20 | 2.94 × 10-3 | 5.82 | 4.07 | 0.30 |
Most obviously dysregulated genes with fold change absolute value > 3 in liver metastatic uveal melanoma (n = 45) vs. non-metastatic tumors (n = 46).
Different gene significant upregulated GO
| Germ cell programmed cell death | 32.29 | 2.80 × 10-3 |
| Developmental programmed cell death | 19.37 | 8.95 × 10-3 |
| Protein retention in ER lumen | 13.84 | 1.80 × 10-2 |
| Germ cell migration | 13.45 | 3.65 × 10-4 |
| Melanocyte differentiation | 9.22 | 8.27 × 10-3 |
| Mitotic cell cycle spindle assembly checkpoint | 8.81 | 4.36 × 10-2 |
| Negative regulation of mitotic metaphase/anaphase transition | 8.81 | 4.36 × 10-2 |
| Pigmentation during development | 8.69 | 1.14 × 10-4 |
| Pigment cell differentiation | 8.61 | 1.01 × 10-2 |
| Antigen processing and presentation of peptide antigen via MHC class I | 7.60 | 1.44 × 10-2 |
| Positive regulation of calcium ion transport into cytosol | 6.46 | 2.26 × 10-2 |
| Regulation of calcium ion transport into cytosol | 5.57 | 1.16 × 10-2 |
| T cell proliferation | 4.78 | 4.95 × 10-2 |
| Regulation of transforming growth factor beta receptor signaling pathway | 4.14 | 3.15 × 10-2 |
| Positive regulation of homeostatic process | 4.04 | 3.42 × 10-2 |
| Response to vitamin A | 3.84 | 4.00 × 10-2 |
| Pigmentation | 3.83 | 9.50 × 10-3 |
| Mitotic cell cycle checkpoint | 3.75 | 4.30 × 10-2 |
| Regulation of calcium ion transport | 3.74 | 5.31 × 10-3 |
| Extracellular matrix organization | 3.73 | 3.63 × 10-4 |
| Alcohol biosynthetic process | 3.67 | 4.62 × 10-2 |
| Regulation of metal ion transport | 3.59 | 3.49 × 10-3 |
| Leukocyte mediated immunity | 3.38 | 5.04 × 10-3 |
| Cellular response to insulin stimulus | 3.32 | 1.83 × 10-2 |
| Regulation of ion transport | 3.26 | 3.51 × 10-3 |
| Lymphocyte mediated immunity | 3.23 | 2.09 × 10-2 |
| Response to organic cyclic substance | 3.20 | 1.30 × 10-3 |
| Response to toxin | 3.18 | 3.98 × 10-2 |
| Double-strand break repair | 3.12 | 4.23 × 10-2 |
| Sphingolipid metabolic process | 3.01 | 2.82 × 10-2 |
| Response to molecule of bacterial origin | 3.00 | 1.70 × 10-2 |
| Adaptive immune response | 2.94 | 3.16 × 10-2 |
| Response to lipopolysaccharide | 2.94 | 3.16 × 10-2 |
| Adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 2.94 | 3.16 × 10-2 |
| Cellular response to hormone stimulus | 2.91 | 2.77 × 10-3 |
| Response to insulin stimulus | 2.91 | 1.22 × 10-2 |
| Membrane lipid metabolic process | 2.79 | 3.91 × 10-2 |
| Activation of MAPK activity | 2.76 | 4.11 × 10-2 |
| Immune effector process | 2.65 | 8.66 × 10-3 |
| Protein processing | 2.59 | 2.27 × 10-2 |
| Extracellular structure organization | 2.57 | 4.72 × 10-3 |
| Response to oxidative stress | 2.56 | 4.95 × 10-3 |
| Positive regulation of MAP kinase activity | 2.53 | 3.86 × 10-2 |
| Regulation of MAP kinase activity | 2.52 | 1.21 × 102 |
| Amine transport | 2.46 | 2.99 × 10-2 |
| Camera-type eye development | 2.41 | 4.79 × 10-2 |
| Carbohydrate biosynthetic process | 2.41 | 4.79 × 10-2 |
| Protein oligomerization | 2.41 | 7.85 × 10-3 |
| Protein maturation | 2.38 | 3.54 × 10-2 |
| Nucleotide biosynthetic process | 2.26 | 1.29 × 102 |
| Nucleobase, nucleoside and nucleotide biosynthetic process | 2.17 | 1.69 × 10-2 |
| Nucleobase, nucleoside, nucleotide and nucleic acid biosynthetic process | 2.17 | 1.69 × 10-2 |
| Cell proliferation | 2.15 | 2.12 × 10-4 |
| Muscle organ development | 2.14 | 1.41 × 102 |
| Regulation of neurogenesis | 2.14 | 3.34 × 10-2 |
| Skeletal system development | 2.13 | 2.21 × 10-3 |
| Response to peptide hormone stimulus | 2.10 | 4.96 × 10-2 |
| Transmembrane receptor protein tyrosine kinase signaling pathway | 2.02 | 2.20 × 10-2 |
| Regulation of nervous system development | 2.02 | 3.63 × 10-2 |
| Nitrogen compound biosynthetic process | 1.99 | 5.98 × 10-3 |
| Enzyme linked receptor protein signaling pathway | 1.98 | 4.86 × 10-3 |
| Response to drug | 1.94 | 3.62 × 10-2 |
| Blood vessel development | 1.84 | 4.11 × 10-2 |
| Response to DNA damage stimulus | 1.82 | 1.20 × 10-2 |
| Induction of apoptosis | 1.82 | 2.14 × 10-2 |
| Induction of programmed cell death | 1.81 | 2.19 × 10-2 |
| Positive regulation of apoptosis | 1.80 | 7.74 × 10-3 |
| Vasculature development | 1.80 | 4.83 × 10-2 |
| Positive regulation of programmed cell death | 1.79 | 8.09 × 10-3 |
| Positive regulation of cell death | 1.78 | 8.74 × 10-3 |
| M phase | 1.77 | 2.70 × 10-2 |
| Response to hormone stimulus | 1.76 | 1.98 × 10-2 |
| Response to endogenous stimulus | 1.75 | 1.46 × 10-2 |
| Cell cycle phase | 1.72 | 1.82 × 10-2 |
| Response to abiotic stimulus | 1.67 | 3.73 × 10-2 |
| Protein kinase cascade | 1.66 | 3.89 × 10-2 |
| Cellular response to stress | 1.65 | 9.67 × 10-3 |
| Response to organic substance | 1.61 | 5.45 × 10-3 |
| Phosphorylation | 1.57 | 5.41 × 10-3 |
| Oxidation reduction | 1.57 | 1.51 × 10-2 |
| Phosphate metabolic process | 1.56 | 2.49 × 10-3 |
| Phosphorus metabolic process | 1.56 | 2.49 × 10-3 |
| Cell cycle process | 1.54 | 2.79 × 10-2 |
| Protein amino acid phosphorylation | 1.50 | 2.49 × 10-2 |
| Immune response | 1.50 | 2.35 × 10-2 |
| Regulation of cell proliferation | 1.44 | 3.02 × 10-2 |
| Regulation of programmed cell death | 1.43 | 2.88 × 10-2 |
| Regulation of cell death | 1.43 | 3.01 × 10-2 |
| Regulation of apoptosis | 1.41 | 3.91 × 10-2 |
Different gene significant downregulated GO
| Calcium-dependent cell-cell adhesion | 9.49 | 3.90 × 10-2 |
| Response to acid | 9.09 | 4.22 × 10-2 |
| Embryonic skeletal system development | 5.67 | 4.04 × 10-3 |
| Response to vitamin | 5.51 | 1.26 × 10-2 |
| Regulation of cell shape | 5.39 | 3.75 × 10-2 |
| Regulation of Rho protein signal transduction | 5.14 | 2.36 × 10-3 |
| Pigmentation | 4.93 | 4.68 × 10-2 |
| Cartilage development | 4.91 | 1.85 × 10-2 |
| Skeletal system morphogenesis | 3.90 | 1.88 × 10-2 |
| Regulation of cell morphogenesis | 3.89 | 9.22 × 10-3 |
| Translational elongation | 3.60 | 4.97 × 10-2 |
| Muscle tissue development | 3.49 | 2.85 × 10-2 |
| Homophilic cell adhesion | 3.33 | 3.40 × 10-2 |
| Regulation of neuron differentiation | 3.28 | 3.59 × 10-2 |
| Embryonic organ morphogenesis | 3.28 | 3.59 × 10-2 |
| Regulation of cell development | 3.19 | 7.23 × 10-3 |
| Regulation of Ras protein signal transduction | 3.12 | 8.25 × 10-3 |
| Muscle organ development | 3.10 | 8.54 × 10-3 |
| Regulation of neurogenesis | 3.07 | 2.66 × 10-2 |
| Response to drug | 3.03 | 9.75 × 10-3 |
| Embryonic organ development | 2.96 | 3.09 × 10-2 |
| Regulation of small GTPase mediated signal transduction | 2.89 | 7.88 × 10-3 |
| Skeletal system development | 2.74 | 4.38 × 10-3 |
| Heart development | 2.71 | 2.85 × 10-2 |
| Regulation of nervous system development | 2.65 | 4.85 × 10-2 |
| Cell-cell adhesion | 2.64 | 1.37 × 10-2 |
| Negative regulation of cell proliferation | 2.62 | 4.07 × 10-3 |
| Cell adhesion | 2.60 | 2.99 × 10-5 |
| Biological adhesion | 2.59 | 3.06 × 10-5 |
| Actin cytoskeleton organization | 2.57 | 3.59 × 10-2 |
| Actin filament-based process | 2.41 | 4.79 × 10-2 |
| Chordate embryonic development | 2.20 | 3.87 × 10-2 |
| Embryonic development ending in birth or egg hatching | 2.18 | 4.03 × 10-2 |
| Cytoskeleton organization | 2.17 | 1.68 × 10-2 |
| Regulation of cell proliferation | 2.03 | 2.54 × 10-3 |
| Response to organic substance | 1.71 | 3.85 × 10-2 |
Figure 2Histogram of signal pathways those were significantly different in liver metastatic and non-metastatic uveal melanoma showing. X axis, negative logarithm of the P value (-LgP); Y axis, the name of the pathway. The larger the -LgP, the smaller the P value.
Figure 3Signal transduction networks of liver metastatic related genes. Circle represents genes, red circle represents the upregulated gene, and blue circle represents the downregulated gene. Arrow represents the activation of (a); straight line represents combine; dotted line represents indirect effects; a represents activation; ex represents gene expression; b represents binding; ind represents indirect effects; inh represents inhibition; u represents ubiquination. For the most interesting nodes, the fold change and p value were added to the YWHAC and FYN.